PDL1 x CD28 bispecific antibody (Xencor)

N/A

Report date: 2026/03/19 16:59:50

Base Information

Drug NamePDL1 x CD28 bispecific antibody (Xencor)

Drug Alias NamePDL1 x CD28 bispecific antibody (Xencor)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CD28Programmed death-ligand 1 blockers

TargetsProgrammed death-ligand 1T-cell-specific surface glycoprotein CD28

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesXencor Inc

China Registration ClassN/A

Develop Information

Active CompaniesXencor Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A